Akribion Therapeutics

Biotechnology Research • Zwingenberg, Hesse, Germany • 11-20 Employees

Company overview

Headquarters	Darmstädter Str. 34, Zwingenberg, 64673, DE
Website	akribion-therapeutics.com
NAICS	541714
Keywords	Biotechnology, Oncology, Therapeutics, Crispr
Founded	2024
Employees	11-20
Socials

Key Contacts at Akribion Therapeutics

Adel Nada

Chair Of The Board Of Directors

Lukas Linnig

Founder & Co-Chief Executive Officer

Michael Krohn

Co-Chief Executive Officer & Co-Founder

Paul Scholz

Co-Founder & Head Of R&D

Akribion Therapeutics Email Formats

Akribion Therapeutics uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@akribion-therapeutics.com), used 61.9% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@akribion-therapeutics.com	61.9%
{first initial}.{last name}	j.doe@akribion-therapeutics.com	38.1%

About Akribion Therapeutics

Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E payload has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence, ensuring that only the targeted cells are affected, leaving healthy cells unharmed. Initially targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), Akribion is exploring additional applications in oncology, autoimmune diseases, fibrosis, and infectious diseases. The flexibility and broad potential of Akribion's technology makes it a promising platform for various therapeutic areas, as by simply changing the guide RNA, the technology can be quickly adapted to target different cells, making it much faster to develop new treatments compared to traditional methods. Founded in 2024 and based in Zwingenberg, Germany, Akribion was spun out of BRAIN Biotech AG, the specialist in biosolutions for industrial applications.

Akribion Therapeutics revenue & valuation

Annual revenue	$1,454,435
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$4,700,000
Total funding	No funding

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Founder/Owner

Entry

Head

Employees by Department

Akribion Therapeutics has 10 employees across 5 departments.

Departments

Number of employees

Funding Data

Akribion Therapeutics has never raised funding before.

Akribion Therapeutics Tech Stack

Discover the technologies and tools that power Akribion Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Apache HTTP Server

Web servers

Twitter Emoji

Font scripts

jQuery

JavaScript libraries

Apple iCloud Mail

Webmail

PHP

Programming languages

Open Graph

Miscellaneous

WordPress

Blogs

UNIX

Operating systems

Sectigo

SSL/TLS certificate authorities

OWL Carousel

JavaScript libraries

MySQL

Databases

Strato

Hosting

Frequently asked questions

Akribion Therapeutics is located in Zwingenberg, Hesse, DE.

Akribion Therapeutics was founded in 2024, making it 2 years old. The company has established itself as a significant player in its industry over this time.

Akribion Therapeutics has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.